Shuttle Pharmaceuticals Holdings, Inc. has announced a reverse stock split scheduled for June 11, 2026, aiming to strengthen its capital structure and comply with Nasdaq listing requirements.
The Gaithersburg-based company will implement a 10-for-1 reverse stock split, reducing its outstanding shares from approximately 6.37 million to around 637,108. This adjustment will also affect shares associated with various equity instruments, including RSUs and warrants. Following the split, Shuttle Pharma's stock will continue to trade on Nasdaq under the existing symbol "SHPH" with a new CUSIP number.
This strategic move is part of Shuttle Pharma's broader plan to enhance its financial stability and maintain compliance with market regulations. The company's platform, Molecule.ai, leverages AI for molecular discovery and drug development, positioning it as a key player in the biotech sector.
The reverse stock split may serve to increase the company's share price, potentially attracting more institutional investors and improving market perception. As Shuttle Pharma continues to innovate in the life sciences arena, its efforts to streamline operations and enhance capital structure could prove crucial for future growth and sustainability.